Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”

We would like to express our sincere gratitude to the reviewers for their thoughtful and detailed comments on our article. We hope that our responses adequately address their concerns and that this exchange of ideas contributes to a broader understanding of the topic. We believe that letters to the...

Full description

Autores:: Aristizábal‑Colorado, David
Ocampo‑Posada, Martín
Rivera‑Martínez, Wilfredo Antonio
Corredor‑Rengifo, David
Rico‑Fontalvo, Jorge
Gómez‑Mesa, Juan Esteban
Duque‑Ossman, John Jairo
Abreu‑Lomba, Alin

Tipo de recurso:

Fecha de publicación:: 2024

Institución:: Universidad Simón Bolívar

Repositorio:: Repositorio Digital USB

Idioma:: eng

id	USIMONBOL2_e3cf698157f394dff850fb4f541f2267
oai_identifier_str	oai:bonga.unisimon.edu.co:20.500.12442/16077
network_acronym_str	USIMONBOL2
network_name_str	Repositorio Digital USB
repository_id_str
dc.title.eng.fl_str_mv	Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”
title	Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”
spellingShingle	Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”
title_short	Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”
title_full	Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”
title_fullStr	Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”
title_full_unstemmed	Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”
title_sort	Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”
dc.creator.fl_str_mv	Aristizábal‑Colorado, David Ocampo‑Posada, Martín Rivera‑Martínez, Wilfredo Antonio Corredor‑Rengifo, David Rico‑Fontalvo, Jorge Gómez‑Mesa, Juan Esteban Duque‑Ossman, John Jairo Abreu‑Lomba, Alin
dc.contributor.author.none.fl_str_mv	Aristizábal‑Colorado, David Ocampo‑Posada, Martín Rivera‑Martínez, Wilfredo Antonio Corredor‑Rengifo, David Rico‑Fontalvo, Jorge Gómez‑Mesa, Juan Esteban Duque‑Ossman, John Jairo Abreu‑Lomba, Alin
description	We would like to express our sincere gratitude to the reviewers for their thoughtful and detailed comments on our article. We hope that our responses adequately address their concerns and that this exchange of ideas contributes to a broader understanding of the topic. We believe that letters to the editor serve as valuable platforms for scholarly discussion and the dissemination of knowledge. We encourage continued dialogue and debate on this important subject.
publishDate	2024
dc.date.accessioned.none.fl_str_mv	2024-12-17T22:49:06Z
dc.date.available.none.fl_str_mv	2024-12-17T22:49:06Z
dc.date.issued.none.fl_str_mv	2024
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.none.fl_str_mv	info:eu-repo/semantics/article
dc.type.spa.none.fl_str_mv	Artículo científico
dc.identifier.citation.eng.fl_str_mv	Aristizábal-Colorado, D., Ocampo-Posada, M., Rivera-Martínez, W.A. et al. Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”. Am J Cardiovasc Drugs (2024). https://doi.org/10.1007/s40256-024-00707-8
dc.identifier.issn.none.fl_str_mv	11753277 (Impreso) 1179187X (Electrónico)
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/20.500.12442/16077
dc.identifier.doi.none.fl_str_mv	https://doi.org/10.1007/s40256-024-00707-8
dc.identifier.url.none.fl_str_mv	https://link.springer.com/article/10.1007/s40256-024-00707-8
identifier_str_mv	Aristizábal-Colorado, D., Ocampo-Posada, M., Rivera-Martínez, W.A. et al. Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”. Am J Cardiovasc Drugs (2024). https://doi.org/10.1007/s40256-024-00707-8 11753277 (Impreso) 1179187X (Electrónico)
url	https://hdl.handle.net/20.500.12442/16077 https://doi.org/10.1007/s40256-024-00707-8 https://link.springer.com/article/10.1007/s40256-024-00707-8
dc.language.iso.none.fl_str_mv	eng
language	eng
dc.rights.eng.fl_str_mv	Attribution-NonCommercial-NoDerivs 3.0 United States
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_14cb
dc.rights.uri.none.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.rights.accessrights.none.fl_str_mv	info:eu-repo/semantics/closedAccess
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivs 3.0 United States http://creativecommons.org/licenses/by-nc-nd/3.0/us/ http://purl.org/coar/access_right/c_14cb
eu_rights_str_mv	closedAccess
dc.format.mimetype.none.fl_str_mv	pdf
dc.publisher.eng.fl_str_mv	Springer Nature
institution	Universidad Simón Bolívar
bitstream.url.fl_str_mv	https://bonga.unisimon.edu.co/bitstreams/d04b3e0f-5e85-4c0f-8365-4e8fba724fb6/download https://bonga.unisimon.edu.co/bitstreams/bc7c6d31-1520-49a1-a835-e32bdf659975/download
bitstream.checksum.fl_str_mv	2f656a26de8af8c32aaacd5e2a33538c 733bec43a0bf5ade4d97db708e29b185
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5
repository.name.fl_str_mv	Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv	repositorio.digital@unisimon.edu.co
_version_	1834107419382251520
spelling	Aristizábal‑Colorado, David68d7494f-ac81-4146-b8df-d989a92ef8ee-1Ocampo‑Posada, Martín4544031f-1f13-4c14-8e55-9951c5a29f64-1Rivera‑Martínez, Wilfredo Antonioe58a20fe-9a93-42a9-91a4-23232b4061ad-1Corredor‑Rengifo, Davidfa08b81d-3aef-4fcb-b2ce-5c770aad6def-1Rico‑Fontalvo, Jorgea156782c-eb0d-4540-a7cb-92742ffaee75-1Gómez‑Mesa, Juan Estebanf3f086f6-6efe-481e-8ce1-a0456b014614-1Duque‑Ossman, John Jairo295ca250-a47d-4d47-ad40-a3e8ac7a1fe6-1Abreu‑Lomba, Alin5c64a8c6-95ae-4e0f-b8c2-cb6d95aa36f3-12024-12-17T22:49:06Z2024-12-17T22:49:06Z2024Aristizábal-Colorado, D., Ocampo-Posada, M., Rivera-Martínez, W.A. et al. Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”. Am J Cardiovasc Drugs (2024). https://doi.org/10.1007/s40256-024-00707-811753277 (Impreso)1179187X (Electrónico)https://hdl.handle.net/20.500.12442/16077https://doi.org/10.1007/s40256-024-00707-8https://link.springer.com/article/10.1007/s40256-024-00707-8We would like to express our sincere gratitude to the reviewers for their thoughtful and detailed comments on our article. We hope that our responses adequately address their concerns and that this exchange of ideas contributes to a broader understanding of the topic. We believe that letters to the editor serve as valuable platforms for scholarly discussion and the dissemination of knowledge. We encourage continued dialogue and debate on this important subject.pdfengSpringer NatureAttribution-NonCommercial-NoDerivs 3.0 United Stateshttp://creativecommons.org/licenses/by-nc-nd/3.0/us/info:eu-repo/semantics/closedAccesshttp://purl.org/coar/access_right/c_14cbAuthor’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”info:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1Peronard R, Mayntz S. Comment on “SGLT2 inhibitors, and how they work beyond the glucosuric effect”. Am J Cardiovasc Drugs 2024. https:// doi. org/ 10. 1007/ s40256- 024- 00706-9.Aristizabal-Colorado D, Corredor-Renfigo D, Vernaza Trujillo D, Galvis C, Abreu-Lomba A. Semaglutide versus empagliflozine, a cohort study with 18 months follow-up (SEMPA18). EV362/#968 E-poster topic: AS10. New medications for treatment of diabetes. Diabetes Technol Ther. 2024;26:A-289. https:// doi. org/ 10. 1089/ dia. 2024. 2525. abstr acts.Corredor-Rengifo D, Vernaza Trujillo D, Galvis C, Aristizabal- Colorado D, Abreu A. Effect of ISGLT2 on hospitalizations for heart failure and metabolic control in diabetic adults over 60 years of age. EV360/#942 e-poster topic: AS10 new medications for treatment of diabetes. Diabetes Technol Ther. 2024;26:A-288. https:// doi. org/ 10. 1089/ dia. 2024. 2525. abstr acts.Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:2099. https:// doi. org/ 10. 1056/ NEJMc 17125 72.Cowan A, Jeyakumar N, Kang Y, Dixon SN, Garg AX, Naylor K, et al. Fracture risk of sodium-glucose cotransporter-2 inhibitors in chronic kidney disease. Clin J Am Soc Nephrol CJASN. 2022;17:835–42. https:// doi. org/ 10. 2215/ CJN. 16171 221.Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors—safety review of real-world data & randomized clinical trials. Curr Problem Cardiol. 2024;49: 102664. https:// doi. org/ 10. 1016/j. cpcar diol. 2024. 102664.See RM, Teo YN, Teo YH, Syn NL, Yip ASY, Leong S, et al. Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials. Pharmacology. 2022;107:123–30. https:// doi. org/ 10. 1159/ 00052 0903.Dong B, Lv R, Wang J, Che L, Wang Z, Huai Z, et al. The extraglycemic effect of SGLT-2is on mineral and bone metabolism and bone fracture. Front Endocrinol. 2022. https:// doi. org/ 10. 3389/ fendo. 2022. 918350.American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024;47:S158–78. https:// doi. org/ 10. 2337/ dc24- S009.Sukhera J. Narrative reviews: flexible, rigorous, and practical. J Grad Med Educ. 2022;14:414–7. https:// doi. org/ 10. 4300/ JGME-D- 22- 00480.1.Aristizábal-Colorado D, Ocampo-Posada M, Rivera-Martínez WA, Corredor-Rengifo D, Rico-Fontalvo J, Gómez-Mesa JE, et al. SGLT2 inhibitors and how they work beyond the glucosuric effect. State of the Art. Am J Cardiovasc Drugs. 2024. https:// doi. org/ 10. 1007/ s40256- 024- 00673-1.Medina Amaya NG, Moreno Cabrera JD. Análisis de costoutilidad de los inhibidores del SGLT2 (Empagliflozina, Dapagliflozina) para el tratamiento de pacientes con falla cardiaca con fracción de eyección reducida (HFrEF) y NYHA II-IV en Colombia [Cost-utility analysis of SGLT2 inhibitors (Empagliflozin, Dapagliflozin) for the treatment of patients with heart failure with reduced ejection fraction (HFrEF) and NYHA II-IV in Colombia]; 2022.Obrador GT, Álvarez-Estévez G, Bellorin-Font E, Bonanno- Hidalgo C, Clavero R, Correa-Rotter R, et al. Documento de consenso sobre nuevas terapias para retrasar la progresión de la enfermedad renal crónica con énfasis en los iSGLT-2: implicaciones para Latinoamérica. Rev Nefrol Latinoam. 2024;21:1–18. https:// doi. org/ 10. 24875/ NEFRO. M2400 0037.ORIGINALCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8905https://bonga.unisimon.edu.co/bitstreams/d04b3e0f-5e85-4c0f-8365-4e8fba724fb6/download2f656a26de8af8c32aaacd5e2a33538cMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/bc7c6d31-1520-49a1-a835-e32bdf659975/download733bec43a0bf5ade4d97db708e29b185MD5320.500.12442/16077oai:bonga.unisimon.edu.co:20.500.12442/160772024-12-17 17:51:01.51http://creativecommons.org/licenses/by-nc-nd/3.0/us/Attribution-NonCommercial-NoDerivs 3.0 United Statesmetadata.onlyhttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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

Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”

Publicaciones similares